JPS6237606B2 - - Google Patents
Info
- Publication number
- JPS6237606B2 JPS6237606B2 JP55064625A JP6462580A JPS6237606B2 JP S6237606 B2 JPS6237606 B2 JP S6237606B2 JP 55064625 A JP55064625 A JP 55064625A JP 6462580 A JP6462580 A JP 6462580A JP S6237606 B2 JPS6237606 B2 JP S6237606B2
- Authority
- JP
- Japan
- Prior art keywords
- medium
- csf
- serum
- glycoprotein
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000002609 medium Substances 0.000 claims description 69
- 102000003886 Glycoproteins Human genes 0.000 claims description 57
- 108090000288 Glycoproteins Proteins 0.000 claims description 57
- 210000002540 macrophage Anatomy 0.000 claims description 37
- 210000001616 monocyte Anatomy 0.000 claims description 34
- 210000004027 cell Anatomy 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 25
- 210000002966 serum Anatomy 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 23
- 239000012264 purified product Substances 0.000 claims description 17
- 210000000130 stem cell Anatomy 0.000 claims description 15
- 210000003714 granulocyte Anatomy 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 210000002700 urine Anatomy 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 9
- 210000005259 peripheral blood Anatomy 0.000 claims description 8
- 239000011886 peripheral blood Substances 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 7
- 239000003104 tissue culture media Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 230000005757 colony formation Effects 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 3
- 238000012360 testing method Methods 0.000 description 39
- 230000000694 effects Effects 0.000 description 38
- 239000000243 solution Substances 0.000 description 33
- 239000000872 buffer Substances 0.000 description 28
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 21
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 18
- 239000006228 supernatant Substances 0.000 description 16
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 14
- 239000001963 growth medium Substances 0.000 description 14
- 239000003814 drug Substances 0.000 description 12
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 11
- 239000012091 fetal bovine serum Substances 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 8
- 238000000108 ultra-filtration Methods 0.000 description 8
- 210000002798 bone marrow cell Anatomy 0.000 description 7
- 229910002092 carbon dioxide Inorganic materials 0.000 description 7
- 239000007853 buffer solution Substances 0.000 description 6
- 239000001569 carbon dioxide Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000012679 serum free medium Substances 0.000 description 6
- 238000005273 aeration Methods 0.000 description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 229920005654 Sephadex Polymers 0.000 description 4
- 239000012507 Sephadex™ Substances 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 201000010000 Agranulocytosis Diseases 0.000 description 3
- 206010018687 Granulocytopenia Diseases 0.000 description 3
- 108010071390 Serum Albumin Proteins 0.000 description 3
- 102000007562 Serum Albumin Human genes 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 239000012888 bovine serum Substances 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000003918 fraction a Anatomy 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012533 medium component Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000003957 anion exchange resin Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 210000002196 fr. b Anatomy 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- -1 iron carboxylic acid Chemical class 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000025113 myeloid leukemia Diseases 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- YBLJYSTXRAWBBH-ZFYZTMLRSA-N (2s,3r,4s,5s,6r)-6-(hydroxymethyl)-2-methyloxane-2,3,4,5-tetrol Chemical compound C[C@]1(O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YBLJYSTXRAWBBH-ZFYZTMLRSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 238000005645 Mc Coy reaction Methods 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002281 colonystimulating effect Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 230000010454 developmental mechanism Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- GGGDNPWHMNJRFN-UHFFFAOYSA-N metrizoic acid Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I GGGDNPWHMNJRFN-UHFFFAOYSA-N 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 210000000948 non-nucleated cell Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229950000550 sodium metrizoate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6462580A JPS56160994A (en) | 1980-05-15 | 1980-05-15 | Preparation of substance capable of differentiating and multiplying human granulocytic stem cell |
| US06/169,107 US4342828A (en) | 1979-07-20 | 1980-07-15 | Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells |
| GB8023347A GB2058081B (en) | 1979-07-20 | 1980-07-17 | Method of producing a substance for curing human granulocytopoenia |
| CA356,422A CA1128881A (en) | 1979-07-20 | 1980-07-17 | Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells |
| DE19803027105 DE3027105A1 (de) | 1979-07-20 | 1980-07-17 | Verfahren zur herstellung eines die proliferation und differenzierung menschlicher granulopoetischer stammzellen stimulierenden faktors |
| SE8005256A SE451850B (sv) | 1979-07-20 | 1980-07-18 | Sett att framstella ett glykoprotein med kend formaga att stimulera bildning och differentiering av humana granulocyter |
| CH550580A CH644520A5 (de) | 1979-07-20 | 1980-07-18 | Verfahren zur herstellung eines die proliferation und differenzierung menschlicher granulopoetischer stammzellen stimulierenden faktors. |
| FR8015923A FR2461500A1 (fr) | 1979-07-20 | 1980-07-18 | Procede de production d'une substance capable de stimuler la proliferation et la differenciation des cellules souches granulopoietiques humaines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6462580A JPS56160994A (en) | 1980-05-15 | 1980-05-15 | Preparation of substance capable of differentiating and multiplying human granulocytic stem cell |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS56160994A JPS56160994A (en) | 1981-12-11 |
| JPS6237606B2 true JPS6237606B2 (de) | 1987-08-13 |
Family
ID=13263619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP6462580A Granted JPS56160994A (en) | 1979-07-20 | 1980-05-15 | Preparation of substance capable of differentiating and multiplying human granulocytic stem cell |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS56160994A (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5874616A (ja) * | 1981-10-30 | 1983-05-06 | Ajinomoto Co Inc | 免疫活性物質とその製造方法 |
-
1980
- 1980-05-15 JP JP6462580A patent/JPS56160994A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS56160994A (en) | 1981-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4342828A (en) | Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells | |
| Burgess et al. | Stimulation by human placental conditioned medium of hemopoietic colony formation by human marrow cells | |
| Dinarello et al. | Demonstration and characterization of two distinct human leukocytic pyrogens | |
| Mendelsohn et al. | The rapid induction by phytohemagglutinin of increased α-aminoisobutyric acid uptake by lymphocytes | |
| Nicola et al. | Separation of functionally distinct human granulocyte-macrophage colony-stimulating factors | |
| Rinaldo Jr et al. | Mechanisms of immunosuppression in cytomegaloviral mononucleosis | |
| Anderson et al. | Abnormalities of polymorphonuclear leukocyte function associated with a heritable deficiency of high molecular weight surface glycoproteins (GP138): common relationship to diminished cell adherence. | |
| Nicola et al. | Preparation of colony stimulating factors from human placental conditioned medium | |
| US20080319163A1 (en) | Method for Isolating and Purifying Immuno-Modulating Polypeptide from Cow Placenta | |
| CN110041425A (zh) | 一种高纯血清白蛋白的制备方法 | |
| Niho et al. | Granulopoietic progenitors in suspension culture: a comparison of stimulatory cells and conditioned media | |
| JPS62223126A (ja) | 血液幹細胞成長因子 | |
| JPS6237606B2 (de) | ||
| Hashimoto et al. | Human neutrophil aggregation and increased adherence to human endothelial cells induced by heat-aggregated IgG and immune complexes. | |
| AU782144B2 (en) | Method for selectively separating blood cells by using lectin | |
| Casillas et al. | Chromatographic behaviour of clotting factors | |
| JPS6237605B2 (de) | ||
| JPS60105621A (ja) | 細胞の分化誘導作用を有する生理活性物質およびその製法 | |
| Lau et al. | Mucopolysaccharide synthesis by human bone marrow in short-term suspension cultures | |
| JPH0154991B2 (de) | ||
| Evans et al. | Evidence for a factor in normal human serum that induces human neutrophilic granulocyte end-stage maturation in vitro | |
| Clarke | THE USE OF PHOSPHORUS 32 IN STUDIES ON PLASMODIUM GALLINACEUM: I. THE DEVELOPMENT OF A METHOD FOR THE QUANTITATIVE DETERMINATION OF PARASITE GROWTH AND DEVELOPMENT IN VITRO | |
| Niskanen et al. | Human T-lymphocyte products stimulate human hemopoietic progenitor cell proliferation in diffusion chambers in vivo | |
| EP0417129B1 (de) | Das lungenwachstum stimulierende und hemmende faktoren für krebstumorzellen | |
| Sieber | Chromatography of human urinary erythropoietin and granulocyte colony-stimulating factor on insolubilized phytohaemagglutinin |